MAPK1 and neoplasm: The anti-tumor potential plus the safety of this therapeutic approach may enable it to be a potent adjuvant to OSCC therapy, particularly for tumors exhibiting less depth and harboring high AKT/ERK activation or high oncogenic miRNA expression.